Akanda (AKAN) Operating Leases (2021 - 2025)

Akanda (AKAN) posted quarterly Operating Leases of $208679.0 for Q4 2025, up 194.46% quarter-over-quarter from $70869.0 in Q2 2025.

Akanda (AKAN) Operating Leases (2021 - 2025) Analysis & Trends

Akanda's Operating Leases history runs 4 years deep, the most recent figure standing at $208679.0 for Q4 2025.

In Q4 2025, Operating Leases changed N/A year-over-year to $208679.0; the TTM figure through Dec 2025 stood at $208679.0 (changed N/A YoY), while the FY2025 annual figure was $208679.0, changed N/A from the prior year.
Operating Leases for Q4 2025 stood at $208679.0, up from $70869.0 in the prior quarter.
The five-year high for Operating Leases was $2.6 million in Q2 2022, with the low at $70869.0 in Q2 2025.
The 4-year median for Operating Leases is $172008.0 (2023), against an average of $920215.5.
The sharpest annual moves came in 2022 and 2023: Operating Leases climbed 6.29% in 2022, then rose 15.91% in 2023.
Akanda's Operating Leases stood at $2.4 million in 2021, then tumbled by 95.17% to $116763.0 in 2022, then gained by 15.91% to $135337.0 in 2023, then jumped by 54.19% to $208679.0 in 2025.
Business Quant data shows AKAN's Operating Leases at $208679.0 in Q4 2025, $70869.0 in Q2 2025, and $135337.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Akanda	266,801.66	266,801.66	-

Download Data